文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

低中危前列腺癌同日行基准标记植入、水凝胶间隔置入及CT/MRI模拟的可行性

Feasibility of Same-Day Prostate Fiducial Markers, Perirectal Hydrogel Spacer Placement, and Computed Tomography and Magnetic Resonance Imaging Simulation for External Beam Radiation Therapy for Low-Risk and Intermediate-Risk Prostate Cancer.
PubMed 文献 · Pract Radiat Oncol · 2021-10-22

本研究纳入21例临床局限性前列腺癌患者,在同一天完成前列腺内基准标记植入、直肠周围水凝胶注射及CT和MRI模拟定位,并于3至4周后行T2 MRI验证扫描。结果显示水凝胶体积变化中位-1.8%±4.5%(P=.27),直肠周围间距及直肠剂量参数均无显著差异,所有计划均满足临床靶区和危及器官约束。

要点

  • 同日完成标记植入、水凝胶置入与模拟定位在操作上可行。
  • 验证扫描时水凝胶体积变化中位-1.8%±4.5%,差异无统计学意义。
  • 直肠V66、V35及D1cc在模拟与验证计划间无显著差异。

核心结论

  • 同日行前列腺内基准标记植入、直肠周围水凝胶注射及CT和MRI模拟定位是可行的,且未显著影响水凝胶体积、位置、临床靶区覆盖或直肠剂量。

研究设计与样本

  • 前瞻性临床试验(NCT01617161)纳入21例临床局限性前列腺癌患者,同日完成标记植入、水凝胶注射及CT和MRI模拟,3至4周后行T2 MRI验证扫描。
  • 将MRI扫描以临床靶区与CT计划扫描融合,生成70 Gy分28次的对比治疗计划。

主要发现

  • 验证扫描距模拟平均24.9±4.6天,距治疗开始平均9.3±4.9天。
  • 前列腺体积两次扫描间无变化(中位67.3±22.1 cm3 vs 64.1±21.8 cm3,P=.64)。
  • 水凝胶体积变化中位-1.8%±4.5%(P=.27),直肠周围间距各测量点均无显著差异。
  • 直肠V66(中位2.3±2.18% vs 2.3±2.28%,P=.99)、V35(中位14.79±7.61 vs 14.67±8.4,P=.73)及D1cc(65.7±9.2 Gy vs 68.2±9.0 Gy,P=.80)均无显著差异。
  • 所有计划均满足临床靶区和危及器官约束。

临床怎么用

  • 对于低危和中危前列腺癌患者,可考虑将基准标记植入、直肠周围水凝胶置入与CT和MRI模拟定位安排在同一天,以加快放疗启动并方便患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The use of prostate fiducial markers and perirectal hydrogel spacers can reduce the acute and late toxic effects associated with prostate radiation therapy. These procedures are usually performed days to weeks before simulation during a separate clinic visit to ensure resolution of procedure-related inflammation. The purpose of this study was to assess whether same-day intraprostatic fiducial marker placement, perirectal hydrogel injection, and computed tomography (CT) and magnetic resonance imaging (MRI) simulation were feasible without adversely affecting hydrogel volume, perirectal spacing, or rectal dose. If feasible, performing these procedures on the same day as simulation would expedite the start of radiation therapy, improve patient convenience, and reduce costs. METHODS AND MATERIALS: Twenty-one patients with clinically localized prostate cancer who were enrolled on a prospective clinical trial (NCT01617161) underwent same-day marker placement, hydrogel injection, and CT and MRI simulation, then underwent T2 MRI verification scans 3 to 4 weeks later. The MRI scans were fused to the CT planning scans by clinical target volumes (CTVs) to generate comparison treatment plans (70 Gy in 28 fractions). Hydrogel volume and symmetry, perirectal spacing, CTV dose, and organ-at-risk dose were evaluated. RESULTS: Verification scans occurred a mean of 24.9 ± 4.6 days after simulation and 9.3 ± 4.9 days after treatment start. Prostate volume did not change between scans (median, 67.3 ± 22.1 cm3 vs 64.1 ± 21.8 cm3; P = .64). The median hydrogel change between simulation and verification was -1.8% ± 4.5% (P = .27). No significant differences in perirectal spacing (midgland: 1.33 ± 0.45 cm vs 1.3 ± 0.7 cm; 1 cm superior: 1.25 ± 0.95 cm vs 1.43 ± 0.91 cm; 1 cm inferior: 1.16 ± 0.28 cm vs 1.41 ± 0.49 cm) were identified. No significant differences in rectal V66 (median 2.3 ± 2.18% vs 2.3 ± 2.28%; P = .99), V35 (median 14.79 ± 7.61 vs 14.67 ± 8.4; P = .73), or D1cc (65.7 ± 9.2 Gy vs 68.2 ± 9.0 Gy; P = .80) were found. All plans met CTV and organ-at-risk constraints. CONCLUSION: Same-day placement of intraprostatic fiducial markers, perirectal hydrogel, and simulation scans was feasible and did not significantly affect hydrogel volume, position, CTV coverage, or rectal dose.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Brenneman RJ, Goddu SM, Andruska N, et al. Feasibility of Same-Day Prostate Fiducial Markers, Perirectal Hydrogel Spacer Placement, and Computed Tomography and Magnetic Resonance Imaging Simulation for External Beam Radiation Therapy for Low-Risk and Intermediate-Risk Prostate Cancer. Pract Radiat Oncol. 2021. PMID: 34695615. doi:10.1016/j.prro.2021.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。